AU2018223739B2 - Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use - Google Patents

Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use Download PDF

Info

Publication number
AU2018223739B2
AU2018223739B2 AU2018223739A AU2018223739A AU2018223739B2 AU 2018223739 B2 AU2018223739 B2 AU 2018223739B2 AU 2018223739 A AU2018223739 A AU 2018223739A AU 2018223739 A AU2018223739 A AU 2018223739A AU 2018223739 B2 AU2018223739 B2 AU 2018223739B2
Authority
AU
Australia
Prior art keywords
fibroblasts
positive
cells
vcf
cardiac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018223739A
Other languages
English (en)
Other versions
AU2018223739A1 (en
Inventor
Takahiro IWAMIYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lymphogenix Ltd
Original Assignee
Lymphogenix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lymphogenix Ltd filed Critical Lymphogenix Ltd
Publication of AU2018223739A1 publication Critical patent/AU2018223739A1/en
Application granted granted Critical
Publication of AU2018223739B2 publication Critical patent/AU2018223739B2/en
Assigned to LYMPHOGENIX LIMITED reassignment LYMPHOGENIX LIMITED Request for Assignment Assignors: METCELA INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018223739A 2017-02-24 2018-02-23 Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use Active AU2018223739B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017033624 2017-02-24
JP2017-033624 2017-02-24
PCT/JP2018/006795 WO2018155651A1 (ja) 2017-02-24 2018-02-23 線維芽細胞を含む心臓疾患を治療するための注射用組成物、及び治療用線維芽細胞の製造方法

Publications (2)

Publication Number Publication Date
AU2018223739A1 AU2018223739A1 (en) 2019-02-14
AU2018223739B2 true AU2018223739B2 (en) 2023-06-22

Family

ID=63253929

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018223739A Active AU2018223739B2 (en) 2017-02-24 2018-02-23 Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use

Country Status (12)

Country Link
US (2) US11096969B2 (enExample)
EP (1) EP3476395B1 (enExample)
JP (2) JP6618066B2 (enExample)
KR (1) KR102407387B1 (enExample)
CN (1) CN109890398B (enExample)
AU (1) AU2018223739B2 (enExample)
CA (1) CA3032654A1 (enExample)
DK (1) DK3476395T3 (enExample)
ES (1) ES2885080T3 (enExample)
IL (1) IL267958B2 (enExample)
SG (1) SG11201900810WA (enExample)
WO (1) WO2018155651A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3110831A1 (en) 2018-08-29 2020-03-05 Metcela Inc. Method for producing fibroblast, and g-csf-positive fibroblast mass
CN109589337B (zh) 2018-12-29 2022-04-26 南京艾尔普再生医学科技有限公司 心肌细胞制剂及其制备方法和应用
IL296125A (en) 2020-03-04 2022-11-01 Metcela Inc Fibroblasts have an increased ability to produce erythropoietin
AU2022231584A1 (en) * 2021-03-04 2023-09-07 Lymphogenix Limited Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same
US20240316113A1 (en) * 2021-09-08 2024-09-26 Metcela Inc. Fibroblast-containing pharmaceutical composition for treating kidney disease
EP4249585A1 (en) * 2022-03-25 2023-09-27 Technische Universität München - TUM Heart tissue models, method of producing heart tissue models and uses of heart tissue models

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057124A1 (en) * 2004-08-26 2006-03-16 Shim Winston S N Methods and compositions for culturing cardiomyocyte-like cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
CA2487254A1 (en) * 2002-05-08 2003-11-20 The Regents Of The University Of California System and method for treating cardiac arrhythmias with fibroblast cells
AU2003239418B2 (en) * 2002-05-08 2008-01-31 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block
US20040161412A1 (en) * 2002-08-22 2004-08-19 The Cleveland Clinic Foundation Cell-based VEGF delivery
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
CN101415458A (zh) * 2003-11-10 2009-04-22 辛弗尼医药有限公司 控制心房纤维性颤动患者心室律的方法
ES2325715B1 (es) * 2007-08-03 2010-06-17 Genetrix, S.L. Poblacion de celulas madre adultas derivadas de tejido adiposo cardiaco y su uso en regeneracion cardiaca.
JP5378743B2 (ja) 2008-09-30 2013-12-25 テルモ株式会社 医療用細胞シートの製造方法
WO2013028968A1 (en) * 2011-08-25 2013-02-28 Wisconsin Alumni Research Foundation 3-dimensional cardiac fibroblast derived extracellular matrix
EP2826855B1 (en) 2012-03-15 2018-08-29 iHeart Japan Corporation Myocardial sheet
US20140072611A1 (en) * 2012-09-07 2014-03-13 Fibrocell Technologies, Inc. Methods and Compositions for Treating Post-Cardial Infarction Damage
GB201309057D0 (en) * 2013-05-20 2013-07-03 Cell Therapy Ltd Method
KR20150009655A (ko) * 2013-07-16 2015-01-27 학교법인 동아학숙 Gcp-2 유전자를 과발현하는 지방 간엽줄기세포를 포함하는 허혈성 질환 치료용 조성물
CA2954743C (en) * 2014-07-11 2022-03-15 Metcela Inc. Cardiac cell culture material

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057124A1 (en) * 2004-08-26 2006-03-16 Shim Winston S N Methods and compositions for culturing cardiomyocyte-like cells

Also Published As

Publication number Publication date
EP3476395A4 (en) 2020-02-26
SG11201900810WA (en) 2019-02-27
CN109890398B (zh) 2024-01-16
CN109890398A (zh) 2019-06-14
IL267958A (en) 2019-09-26
AU2018223739A1 (en) 2019-02-14
US20210346436A1 (en) 2021-11-11
EP3476395A1 (en) 2019-05-01
CA3032654A1 (en) 2018-08-30
IL267958B2 (en) 2023-08-01
JP7072135B2 (ja) 2022-05-20
IL267958B1 (en) 2023-04-01
EP3476395B1 (en) 2021-07-21
WO2018155651A1 (ja) 2018-08-30
DK3476395T3 (da) 2021-08-16
JP2019218408A (ja) 2019-12-26
JP6618066B2 (ja) 2019-12-11
US20190224250A1 (en) 2019-07-25
KR20190117468A (ko) 2019-10-16
US11096969B2 (en) 2021-08-24
KR102407387B1 (ko) 2022-06-10
JPWO2018155651A1 (ja) 2019-11-07
ES2885080T3 (es) 2021-12-13

Similar Documents

Publication Publication Date Title
AU2018223739B2 (en) Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use
Bao et al. C-Kit Positive cardiac stem cells and bone marrow–derived mesenchymal stem cells synergistically enhance angiogenesis and improve cardiac function after myocardial infarction in a paracrine manner
US20210145893A1 (en) Compositions to amplify cardiac stem cells in vitro and in viv
JP7428389B2 (ja) 線維芽細胞の製造方法及びｇ－ｃｓｆ陽性線維芽細胞集団
US20200085875A1 (en) Platelet vesicle-engineered cells for targeted tissue repair
CN114224916B (zh) 用于治疗心力衰竭的方法
Fatkhudinov et al. Bone Marrow‐Derived Multipotent Stromal Cells Promote Myocardial Fibrosis and Reverse Remodeling of the Left Ventricle
WO2017012226A1 (zh) 间质干细胞、其克隆源性扩增的方法、其分离方法及其应用
CA2767825A1 (en) Cardiac tissue-derived cells
Guo et al. Young human PRP promotes the rejuvenation of aged bone marrow mesenchymal stem cells and the therapeutic effect on ischemic heart disease
EP2205251B1 (en) A method to amplify cardiac stem cells in vitro and in vivo
RU2800644C2 (ru) Способ получения фибробластов и г-ксф-положительная фибробластная масса
WO2024176514A1 (ja) 心臓内幹細胞を含む細胞集団
Kinugawa et al. Safety and Efficacy of Autologous Skeletal Myoblast Sheets (TCD-5 1073) for the Treatment of Severe Chronic Heart

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: LYMPHOGENIX LIMITED

Free format text: FORMER OWNER(S): METCELA INC.